Vor Biopharma

Clinical trials sponsored by Vor Biopharma, explained in plain language.

Vor Biopharma VOR NASDAQ

Develops engineered hematopoietic stem cell therapies for blood cancers.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New hope for muscle weakness: drug trial targets myasthenia gravis Results expected May 2027 (estimated) May already have reported ↗ 🚀 Make-or-break

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1 Terminated 1

Lupus drug trial halted early: what we know

Disease control Stopped early

This study tested a weekly injection called telitacicept against a placebo in 91 people with moderate-to-severe lupus. The goal was to see if the drug could reduce disease activity and allow lower steroid doses. However, the trial was terminated early, so we have less information…

Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

Vor Biopharma

Upcoming readouts

Lupus drug trial halted early: what we know